Clinical observatiin of gemcitabine or vinorelbine combined with cisplatin in the treatment of late-term patients with non-small-cell lung cancer

Objective To estimate the efficacy,toxicity and side effects of the tw o combinations of gemcitabine cisplatin and vinorelbine cisplatin in the t reatment of late-term patients with non-small cell lung cancer (NSCLC). Methods 62 advanced patients with NSCLC diagnosed by pathology or cytology were enrolle d into two groups randomly,each group have 31 patients.The group A with 31 patie nts received gemcitabine 1200mg/m2 on d 1,8,15 and cisplatin 80mg/m2 in the firs t day;the group B with another 31 patients received vinorelbine 25 mg/m2 in the d 1,8 and cisplatin 80mg/m2 in the first day.Both regiments had 21-day cycle,i e .,three weeks repeated and the efficacy was estimated after 3 periods. Results T he efficacy with group A and B were 48.3%(15/31)and 51.1%(16/31)respectively..Th ere was no significant difference(P0.005)between two groups from the view of ac corting.The median ailment development time were 4.8 and 3.8 months for group A and B,respectively and there had some accounting difference(P0.005).The median survival time were 11 and 10.5 months and no significant difference appeared(P0 .005).Finaly the 1-year survival time were 45.2% for group A and 41.9% for group Band there were also no significant difference(P0.05).The thromasthenia with g roup A was little higher than that or group B(P0.001), but the lurcopeniano,nau sea and vomiting,and venous inflammation.with group A were apparently lower than that of group B(P0.005). Conclusion There were no significant difference with group A and B on efficacy,median survival time and 1-year survival time,but the re had little advantage with group A on median ailment development time